Ashley Hall is Chief Development Officer of OnKure Therapeutics, Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Structure Therapeutics Inc.
20 Sep 24
3
Structure Therapeutics Inc.
20 Sep 24
4
Reneo Pharmaceuticals, Inc.
29 Aug 23
144
Reneo Pharmaceuticals, Inc.
28 Aug 23
4
Reneo Pharmaceuticals, Inc.
13 Dec 22
4
Reneo Pharmaceuticals, Inc.
15 Nov 21
3
Reneo Pharmaceuticals, Inc.
14 Oct 21
4
Esperion Therapeutics, Inc.
29 Jan 21
3
Esperion Therapeutics, Inc.
28 Feb 20
Recent insider trades
| Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Sep 24 | GPCR Structure Therapeutics | Ordinary Shares | Grant | Acquire A | No | No | 0 | 67,290 | 0.00 | 67,290 |
| 18 Sep 24 | GPCR Structure Therapeutics | Share option Ordinary Shares | Grant | Acquire A | No | No | 12.75 | 82,890 | 1.06 mm | 82,890 |
| 28 Aug 23 | OKUR OnKure Therapeutics | Common Stock | Sell | Dispose S | No | No | 6.2757 | 15,625 | 98.06 k | 39,600 |
| 28 Aug 23 | OKUR OnKure Therapeutics | Common Stock | Option exercise | Acquire M | No | No | 1.8 | 15,625 | 28.13 k | 55,225 |
| 28 Aug 23 | OKUR OnKure Therapeutics | Stock option Common Stock | Option exercise | Dispose M | No | No | 1.8 | 15,625 | 28.13 k | 109,375 |